학술논문
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
Document Type
Article
Author
Source
In Annals of Oncology February 2021 32(2):197-207
Subject
Language
ISSN
0923-7534